February 27, 2026
bioMérieux – 2025 Financial Results
Consolidated sales amounted to €4,070 million in 2025, up 6.2% like-for-like from €3,980 million in the prior year period. Reported growth stood at +2.3% for the period.
Media & Press relations
Our latest press releases
Swipe for more
-
February 18, 2026
bioMérieux launches SMARTBIOME™ to help food manufacturers gain deeper insights into spoilage and protect product quality
bioMérieux, a world leader in the field of in vitro diagnostics, today announces the launch of SMARTBIOME™, an innovative solution designed to help food manufacturers better understand, control and prevent microbiological spoilage. By combining high‑precision DNA sequencing, advanced bioinformatics and bioMérieux’s microbiology expertise, SMARTBIOME™ provides actionable insights to protect product quality, reduce waste and better preserve consumer safety. -
January 22, 2026
bioMérieux Acquires Accellix to Elevate Pharmaceutical Quality Control and Accelerate Advanced Therapies
bioMérieux, a world leader in the field of in vitro diagnostics, announces the acquisition of Accellix, a US company specializing in rapid, automated flow cytometry solutions for cell and gene therapy quality control. With this strategic transaction, bioMérieux strengthens its Pharmaceutical Quality Control activity and invests in innovative solutions that will support the growing advanced therapy market and improve patient outcomes worldwide. -
December 22, 2025
WellStreet Urgent Care, bioMérieux celebrate 200,000 patients served through BIOFIRE® SPOTFIRE® tests in urgent care clinics across Georgia, Ohio and South Carolina
WellStreet Urgent Care and bioMérieux announce the 200,000th patient diagnosed via the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel Mini in their urgent clinics since the first instrument placement in February 2025.
Helpful Resources
